Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
about
Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteersNovel and emerging therapies for the treatment of polycythemia veraAntiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C.Ruxolitinib for the treatment of patients with polycythemia vera.Synergistic Antiviral activity of Sofosbuvir and Type -I Interferons (α and β) against Zika virus.Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series.Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.New insight into the enhanced effect of pegylated interferon-α.
P2860
Q34526617-8039103B-E24B-46F9-B339-E52D606D9CD4Q36214486-00403893-12BB-401A-8F49-CA7199E70B4CQ37069633-BD5B41E0-52C8-4498-BB90-50B3CB428D83Q38076757-BD38A1DE-BBA8-4C8A-92F3-8C3271295908Q38484321-43B1ABEE-2A0D-4E2F-808F-BDA1589BD1D8Q38693891-C64FF921-5AC8-4ACD-A2DF-122841EF05A9Q41392572-D01F7A67-D4FA-46FD-B0FA-7C8D242EEBA3Q42210289-54978713-06CD-4DB3-86CD-2A75F00DBBD4Q42841419-BBB8BA76-05A5-42B2-83E3-FD49F180DB49Q47231847-9B60F9B5-2D34-4322-A94E-DA9A516E5340Q53940851-F3B7ABDF-91CF-4B7A-9E42-FAC58B2F170A
P2860
Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetic and pharmacody ...... crossover, double-blind study.
@ast
Pharmacokinetic and pharmacody ...... crossover, double-blind study.
@en
type
label
Pharmacokinetic and pharmacody ...... crossover, double-blind study.
@ast
Pharmacokinetic and pharmacody ...... crossover, double-blind study.
@en
prefLabel
Pharmacokinetic and pharmacody ...... crossover, double-blind study.
@ast
Pharmacokinetic and pharmacody ...... crossover, double-blind study.
@en
P2093
P2860
P356
P1433
P1476
Pharmacokinetic and pharmacody ...... crossover, double-blind study.
@en
P2093
Alina Díaz-Machado
Carlos A González-Delgado
Carmen M Valenzuela-Silva
Cimara H Bermúdez-Badell
FarmaPEG Study Group
Fidel R Castro-Odio
Hugo Nodarse-Cuní
Idrian García-García
Iraldo Bello-Rivero
Joel Ferrero-Bibilonia
P2860
P2888
P356
10.1186/1471-2210-10-15
P577
2010-11-23T00:00:00Z
P5875
P6179
1003833681